Summary
Global Markets Direct’s, ‘Nasopharyngeal Cancer - Pipeline Review, H1 2016’, provides an overview of the Nasopharyngeal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
- The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ambrx, Inc.
Atara Biotherapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Betta Pharmaceuticals Co. Ltd.
BioDiem Ltd
Biomics Biotechnologies Co., Ltd.
Celgene Corporation
Cell Medica Limited
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Molecular Partners AG
Ono Pharmaceutical Co., Ltd.
Pharmacyclics, Inc.
Sapvax
Shenzen SiBiono GeneTech Co., Ltd
Theravectys SA
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Nasopharyngeal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Nasopharyngeal Cancer - Overview 11
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 12
Nasopharyngeal Cancer - Therapeutics under Development by Companies 13
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 15
Nasopharyngeal Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Nasopharyngeal Cancer - Products under Development by Companies 19
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 20
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 21
Ambrx, Inc. 21
Atara Biotherapeutics, Inc. 22
AVEO Pharmaceuticals, Inc. 23
Betta Pharmaceuticals Co. Ltd. 24
BioDiem Ltd 25
Biomics Biotechnologies Co., Ltd. 26
Celgene Corporation 27
Cell Medica Limited 28
F. Hoffmann-La Roche Ltd. 29
GlaxoSmithKline Plc 30
Merck & Co., Inc. 31
Molecular Partners AG 32
Ono Pharmaceutical Co., Ltd. 33
Pharmacyclics, Inc. 34
Sapvax 35
Shenzen SiBiono GeneTech Co., Ltd 36
Theravectys SA 37
Nasopharyngeal Cancer - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
abexinostat hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
azacitidine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cellular Immunotherapy for Multiple Sclerosis - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cellular Immunotherapy for Oncology - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cellular Immunotherapy for Oncology and Central Nervous System - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CMD-003 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DC-120 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EBV-nRNA - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Epstein-Barr virus vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ficlatuzumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Gene Therapy to Activate p53 for Oncology - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GSK-2849330 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
icotinib hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MK-2206 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MP-0250 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MVA vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NEO-212 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
nimotuzumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
nivolumab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RO-5203280 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SV-638 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TT-10 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Vaccine for Oncology - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Nasopharyngeal Cancer - Recent Pipeline Updates 101
Nasopharyngeal Cancer - Dormant Projects 125
Nasopharyngeal Cancer - Discontinued Products 126
Nasopharyngeal Cancer - Product Development Milestones 127
Featured News & Press Releases 127
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129
List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2016 11
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H1 2016 21
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 22
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 23
Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 24
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2016 25
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 26
Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H1 2016 27
Nasopharyngeal Cancer - Pipeline by Cell Medica Limited, H1 2016 28
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 30
Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2016 31
Nasopharyngeal Cancer - Pipeline by Molecular Partners AG, H1 2016 32
Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 33
Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 34
Nasopharyngeal Cancer - Pipeline by Sapvax, H1 2016 35
Nasopharyngeal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H1 2016 36
Nasopharyngeal Cancer - Pipeline by Theravectys SA, H1 2016 37
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Stage and Target, H1 2016 40
Number of Products by Stage and Mechanism of Action, H1 2016 42
Number of Products by Stage and Route of Administration, H1 2016 44
Number of Products by Stage and Molecule Type, H1 2016 46
Nasopharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 101
Nasopharyngeal Cancer - Dormant Projects, H1 2016 125
Nasopharyngeal Cancer - Discontinued Products, H1 2016 126
List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2016 11
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Top 10 Targets, H1 2016 39
Number of Products by Stage and Top 10 Targets, H1 2016 39
Number of Products by Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Routes of Administration, H1 2016 43
Number of Products by Stage and Routes of Administration, H1 2016 43
Number of Products by Molecule Types, H1 2016 45
Number of Products by Stage and Molecule Types, H1 2016 45
